The evolution of Bruton's tyrosine kinase (BTK) inhibitors has significantly altered the treatment landscape for various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Covalent BTK...
Read moreDetails









